Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-10-08

Clinical Trial Update: A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome [Phase 3]

View source ↗

Summary

Phase 3 study of lorcaserin as an adjunctive treatment for Dravet syndrome was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lorcaserin (lorcaserin)

Snippet

Sponsor: Eisai Inc. | Conditions: Epilepsies, Myoclonic | Phase 3 | Status: TERMINATED | Results posted: 2025-10-08